Biologics CDMO Secondary Packaging Market Size, Share and Growth Report (2025–2034)

The Biologics CDMO Secondary Packaging Market is witnessing steady growth as pharmaceutical companies increasingly outsource secondary packaging operations to contract development and manufacturing organizations (CDMOs). Secondary packaging activities, including labeling, cartoning, serialization, and protective packaging, play a critical role in maintaining product integrity while ensuring regulatory compliance. The growing production of biologics, coupled with the rising demand for specialized packaging solutions, continues to support market expansion.

Request Sample Link:
https://packagingmarketinsights.com/report/biologics-cdmo-secondary-packaging-market/request-sample

Market Overview

The biologics CDMO secondary packaging market size was valued at approximately USD 5.6 billion in 2025 and is expected to reach USD 6.1 billion in 2026. The market is projected to expand to nearly USD 10.9 billion by 2034, reflecting a CAGR of 7.5% during 2025–2034.

The market is benefiting from the increasing adoption of biologics, including monoclonal antibodies, vaccines, and gene therapies, which require specialized packaging solutions to maintain stability throughout storage and transportation. Pharmaceutical companies are increasingly relying on CDMOs to deliver efficient, compliant, and high-quality packaging services while allowing them to focus on research and development.

Market Size and Forecast

The biologics CDMO secondary packaging market demonstrates strong growth potential throughout the forecast period.

Market Highlights

• Market Size (2025): USD 5.6 Billion

• Market Size (2026): USD 6.1 Billion

• Forecast Market Size (2034): USD 10.9 Billion

• CAGR (2025–2034): 7.5%

Several factors contribute to this growth, including increasing biologics production, greater outsourcing of packaging operations, and the need for advanced secondary packaging technologies that support regulatory compliance and product protection.

Market Drivers

Expansion of Biologics and Biosimilars Production

The rapid growth in biologics and biosimilars production is a major driver of the biologics CDMO secondary packaging market. As these therapies become increasingly important in treating complex diseases, pharmaceutical companies require specialized secondary packaging solutions that maintain product quality and safety. CDMOs provide efficient and compliant packaging services, making them valuable partners in supporting expanding biologics pipelines.

Increasing Outsourcing by Pharmaceutical Companies

Pharmaceutical companies continue to outsource packaging operations to CDMOs to improve operational efficiency and reduce costs. Outsourcing enables manufacturers to concentrate on core activities such as research and development while leveraging the specialized expertise and infrastructure offered by CDMOs. Increasingly complex packaging requirements further strengthen demand for outsourced secondary packaging services.

Market Challenges

Stringent Regulatory Requirements and Compliance Challenges

One of the key challenges facing the biologics CDMO secondary packaging market is compliance with stringent international regulatory standards. Packaging providers must invest significantly in technologies such as serialization and track-and-trace systems to meet evolving regulatory requirements.

Frequent updates to regulations also require continuous adaptation, increasing operational complexity and costs. These compliance requirements can slow market growth, particularly for smaller organizations with limited resources.

Market Opportunities

Growth of Personalized Medicine and Specialty Therapies

The increasing emphasis on personalized medicine presents significant opportunities for the biologics CDMO secondary packaging market. Customized therapies require flexible packaging solutions capable of handling smaller production batches and unique packaging specifications. CDMOs are well positioned to provide these tailored packaging services.

Expansion in Emerging Markets

Emerging markets across Asia Pacific, Latin America, and the Middle East are creating new growth opportunities. Expanding pharmaceutical manufacturing capabilities and improving healthcare infrastructure are driving greater demand for secondary packaging services. CDMOs are expanding their regional presence to capitalize on these opportunities.

Market Segmentation

By Type

Cartons accounted for approximately 31.4% of the market in 2024, making them the leading packaging type due to their versatility, cost-effectiveness, and protective capabilities for biologic products.

Smart packaging solutions are projected to register the fastest CAGR of 8.2% during the forecast period. Technologies such as RFID, sensors, and serialization support improved product monitoring, safety, and traceability.

Type segments include:

• Cartons

• Labels

• Inserts & Leaflets

• Smart Packaging

By Material

Plastic packaging represented approximately 48.9% of the market in 2024, supported by its durability, flexibility, and ability to protect biologics during transportation and storage.

Paper-based packaging is expected to grow at a CAGR of 7.1% due to increasing emphasis on recyclable and biodegradable materials.

Material segments include:

• Plastic

• Paper & Paperboard

• Metal

By End-Use

Biopharmaceutical applications held approximately 52.6% of the market in 2024, supported by the growing demand for specialized packaging that ensures product safety and regulatory compliance.

Cell and gene therapy packaging is anticipated to grow at the fastest CAGR of 8.5%, driven by increasing adoption of advanced therapies requiring highly specialized packaging.

End-use segments include:

• Biopharmaceutical

• Cell & Gene Therapy

• Clinical Trials

Regional Analysis

Asia Pacific

Asia Pacific dominated the biologics CDMO secondary packaging market with a 36.8% share in 2025 and is expected to grow at the highest CAGR of 7.8%. Rapid pharmaceutical production and expanding contract manufacturing services continue to support regional growth. China remains the leading country due to its substantial manufacturing capacity.

North America

North America accounted for approximately 34.2% of the market in 2025 and is projected to grow at a CAGR of 7.2%. The United States leads the regional market, supported by a strong pharmaceutical industry and significant investment in biologics research and development.

Europe

Europe captured approximately 27.6% of the market share in 2025 and is expected to expand at a CAGR of 7.1%. Germany leads the region, supported by its established pharmaceutical manufacturing base and growing adoption of sustainable packaging solutions.

Middle East & Africa

The Middle East & Africa represented approximately 5.4% of the market in 2025 and is expected to grow at a CAGR of 6.9%. Saudi Arabia is a key contributor, driven by ongoing development of local pharmaceutical manufacturing capabilities.

Latin America

Latin America accounted for approximately 6.0% of the market in 2025 and is projected to grow at the fastest CAGR of 7.8%. Brazil leads the region, supported by an expanding pharmaceutical industry and increasing outsourcing of packaging services.

Key Players

The biologics CDMO secondary packaging market is moderately competitive, with companies focusing on innovation, service expansion, partnerships, and acquisitions to strengthen their market presence.

Some of the leading market participants include:

1. Catalent Inc.

2. Lonza Group

3. Thermo Fisher Scientific Inc.

4. Recipharm AB

5. PCI Pharma Services

6. Sharp Packaging Services

7. West Pharmaceutical Services

8. Almac Group

Conclusion

The Biologics CDMO Secondary Packaging Market is expected to maintain steady growth through 2034, driven by increasing biologics production, greater outsourcing by pharmaceutical companies, and rising demand for specialized secondary packaging solutions. Continued investment in smart packaging technologies, sustainable materials, and customized packaging services is expected to support long-term market development.

With a market size projected to reach USD 10.9 billion by 2034 at a CAGR of 7.5%, the biologics CDMO secondary packaging market presents significant opportunities across packaging types, materials, end-use applications, and regional markets. Growing pharmaceutical manufacturing, expanding healthcare infrastructure, and increasing demand for compliant packaging solutions will continue to shape the market throughout the forecast period.

Report Link:
https://packagingmarketinsights.com/report/biologics-cdmo-secondary-packaging-market